Rilutek® (Riluzole) — The Gold Standard Treatment for Amyotrophic Lateral Sclerosis (ALS)

The First and Most Established Disease-Modifying Treatment for Motor Neuron Disease

Rilutek® (Riluzole) is a glutamate inhibitor and the first disease-modifying treatment approved for Amyotrophic Lateral Sclerosis (ALS) — also known as Motor Neuron Disease (MND) or Lou Gehrig’s Disease. While Rilutek does not cure ALS or reverse existing damage, it slows disease progression and extends survival by reducing glutamate-mediated excitotoxicity in motor neurons — the primary mechanism driving motor neuron death in ALS.

A.K. Pharma is a trusted medicine distributor in Delhi supplying genuine Rilutek (Riluzole) to hospitals, neurology centres, ALS clinics, and pharmacies across India. Manufactured by Sanofi, a global leader in neuroscience medicines, Rilutek remains the cornerstone of ALS pharmacological management after more than 25 years of clinical use.

What is Rilutek (Riluzole)?

Rilutek contains Riluzole — a benzothiazole compound that inhibits glutamatergic neurotransmission through multiple mechanisms. Glutamate is the primary excitatory neurotransmitter in the central nervous system. In ALS excessive glutamate accumulation causes excitotoxicity — overstimulation of motor neurons leading to calcium influx, oxidative stress, and ultimately motor neuron death.

By reducing glutamate release and blocking its effects, Rilutek protects motor neurons from excitotoxic damage — slowing the progressive loss of motor function that characterises ALS. Riluzole also has neuroprotective effects through sodium channel blockade and direct effects on neuronal membranes.

Full prescribing information is available at the FDA label for Riluzole.

Clinical Studies and Evidence

Pivotal ALS Trial — Bensimon et al. (1994) Published in the New England Journal of Medicine (1994), this landmark double-blind placebo-controlled trial demonstrated that Riluzole 100mg/day significantly extended survival in patients with ALS — with median survival benefit of approximately 3 months at 18 months follow-up and 21% reduction in the risk of death or tracheostomy compared to placebo.

Lacomblez et al. Dose-Ranging Trial (1996) Published in The Lancet (1996), this large multicentre dose-ranging trial confirmed Riluzole 100mg/day as the optimal dose — demonstrating significant survival benefit with 100mg daily while higher doses did not improve outcomes.

Cochrane Systematic Review (2012) A Cochrane systematic review of all Riluzole trials confirmed Riluzole significantly extends survival in ALS — with a 9% increase in the probability of surviving 12 months — establishing it as the standard of care for ALS worldwide.

Long-Term Real-World Evidence Multiple real-world studies across Europe, North America, and Asia have confirmed that Rilutek use in routine clinical practice extends survival in ALS patients by approximately 3-6 months — consistent with clinical trial data — with sustained benefit over long-term use.

Combination with Edaravone Recent studies have explored combining Riluzole with Edaravone — another approved ALS treatment — with some evidence suggesting additive neuroprotective effects through complementary mechanisms (glutamate inhibition + free radical scavenging).

Available Strengths

Rilutek is available as:

• 50mg Film-coated Tablets

The recommended dose is 50mg orally twice daily — total daily dose 100mg. Tablets should be taken on an empty stomach — at least 1 hour before or 2 hours after meals — as food significantly reduces Riluzole absorption.

Indications — What Rilutek is Used For

• Treatment of Amyotrophic Lateral Sclerosis (ALS) — also known as Motor Neuron Disease (MND) or Lou Gehrig’s Disease
• Extends survival and delays the need for tracheostomy in patients with ALS
• Indicated for both limb-onset and bulbar-onset ALS

Note: Rilutek is not a cure for ALS — it does not reverse existing motor neuron damage or restore lost function. Its benefit is in slowing disease progression and extending survival.

For detailed indication information refer to MedlinePlus Riluzole and ALS Association treatment information.

Key Benefits of Rilutek

First Disease-Modifying ALS Treatment Rilutek was the first medicine to demonstrate a survival benefit in ALS — a disease with previously no disease-modifying treatment options. This established proof of concept that ALS progression can be modified pharmacologically.

Proven Survival Extension Multiple clinical trials and real-world studies consistently demonstrate Rilutek extends survival by approximately 3-6 months — a clinically meaningful benefit in a rapidly progressive disease with median survival of 2-5 years from diagnosis.

Delays Tracheostomy Rilutek delays the need for tracheostomy — a major clinical milestone in ALS representing severe respiratory compromise — improving quality of life and reducing the burden of invasive ventilation.

25+ Years of Clinical Experience With over 25 years of post-approval clinical use, Rilutek has the most comprehensive safety and efficacy dataset of any ALS treatment — enabling confident long-term prescribing decisions.

Well-Tolerated Oral Therapy Twice daily oral tablet administration allows outpatient treatment without the need for infusions or injections, maintaining patient independence and quality of life.

Complementary to Supportive Care Rilutek’s disease-modifying benefit complements the multidisciplinary supportive care approach (physiotherapy, speech therapy, nutritional support, respiratory support) that forms the cornerstone of ALS management.

How Rilutek Works

ALS is characterised by the progressive degeneration and death of both upper and lower motor neurons. While the exact cause of ALS remains incompletely understood, glutamate-mediated excitotoxicity is a well-established contributor to motor neuron death:

• Glutamate is released at synapses and binds to NMDA and AMPA receptors on motor neurons
• In ALS glutamate clearance is impaired — leading to excessive receptor activation
• Overstimulation of glutamate receptors causes excessive calcium influx into motor neurons
• Elevated intracellular calcium activates destructive enzymes and generates free radicals
• This cascade leads to mitochondrial dysfunction, oxidative stress, and motor neuron death

Rilutek interrupts this cycle through multiple complementary mechanisms:

• Inhibits voltage-gated sodium channels — reducing action potential-dependent glutamate release from presynaptic terminals
• Blocks glutamate receptor activation — reducing postsynaptic excitotoxicity
• Activates G-protein-dependent signalling — modulating excitatory neurotransmission
• Direct neuroprotective effects — stabilising neuronal membranes and reducing oxidative stress

For a detailed mechanism overview refer to the ALS Association and European ALS/MND Association educational resources.

ALS Treatment Landscape — Where Rilutek Fits

Dosage and Administration

• Recommended Dose: 50mg orally twice daily — total daily dose 100mg
• Timing: On an empty stomach — at least 1 hour before or 2 hours after meals
• Food Effect: High-fat meals reduce Riluzole Cmax by 44% and AUC by 17% — consistently take on empty stomach
• Duration: Lifelong — continue until patient and physician decide benefits no longer outweigh risks
• Missed Dose: Take as soon as possible — if close to next dose skip and resume normal schedule

Full dosing guidelines available at Drugs.com Riluzole Dosage.

Who Should Use Rilutek

Rilutek is prescribed for:

• All patients with a confirmed diagnosis of ALS/MND — regardless of disease stage
• Both limb-onset and bulbar-onset ALS
• Early initiation is preferred — greatest benefit when started early in disease course
• Patients should continue Rilutek alongside all supportive care measures

Rilutek is prescribed by neurologists and ALS specialists. A.K. Pharma supplies Rilutek to hospitals, neurology centres, ALS clinics, and pharmacies across Delhi and India.

Possible Side Effects

Common side effects include asthenia (weakness), nausea, diarrhoea, abdominal pain, dizziness, somnolence, and elevated liver enzymes.

Serious side effects include:

• Hepatotoxicity — elevated liver enzymes occur in approximately 50% of patients, severe hepatotoxicity is rare but possible
• Neutropenia — rare cases of severe neutropenia reported
• Interstitial lung disease — rare but serious pulmonary reactions
• Hypersensitivity reactions

Full side effect information available at FDA Riluzole Safety Information.

Precautions

• Monitor liver function tests (ALT/AST) at baseline, monthly for first 3 months, quarterly for remainder of first year, then annually
• Discontinue if ALT exceeds 5 times upper limit of normal
• Monitor complete blood count — particularly if fever develops (neutropenia risk)
• Use with caution in patients with hepatic impairment — lower starting dose may be considered
• Use with caution in patients with renal impairment
• Avoid alcohol during treatment — additive hepatotoxicity risk
• Not recommended during pregnancy
• Refer to WHO Neurological Disorders Fact Sheet for broader neurological disease context

Storage and Handling

• Store at room temperature between 20°C and 25°C
• Protect from bright light
• Keep in original packaging
• Keep out of reach of children

As a responsible medicine distributor in Delhi, A.K. Pharma stores all medicines including Rilutek under manufacturer-recommended conditions ensuring product integrity for every supply.

Manufacturer Information

Rilutek (Riluzole) is manufactured by Sanofi, a global pharmaceutical company with extensive neuroscience expertise. Riluzole received FDA approval in December 1995 as the first treatment approved for ALS. A.K. Pharma supplies only genuine Rilutek sourced from authorized Sanofi distributors.

Related Neurology Medicines Available at A.K. Pharma

• Exelon Patch (Rivastigmine) — cholinesterase inhibitor for Alzheimer’s and Parkinson’s dementia
• Sabril (Vigabatrin) — GABA transaminase inhibitor for infantile spasms and refractory epilepsy
• Browse all Neurology Medicines available at A.K. Pharma

Frequently Asked Questions

Q. What is Rilutek used for? Rilutek (Riluzole) is the primary disease-modifying treatment for Amyotrophic Lateral Sclerosis (ALS) — also known as Motor Neuron Disease. It slows disease progression and extends survival by reducing glutamate-mediated excitotoxicity in motor neurons. More information available at MedlinePlus.

Q. What is the generic name of Rilutek? The generic name of Rilutek is Riluzole. It belongs to the glutamate inhibitor class of neuroprotective medicines.

Q. How much does Rilutek extend survival in ALS? Clinical trials and real-world studies consistently demonstrate Rilutek extends survival in ALS by approximately 3-6 months. While this may seem modest, in a disease with no cure and median survival of 2-5 years from diagnosis, this represents a clinically meaningful benefit — particularly when combined with optimal supportive care.

Q. Should Rilutek be started early in ALS? Yes. Early initiation of Rilutek is recommended — the greatest benefit is seen when treatment is started early in the disease course before significant motor neuron loss has occurred. All patients with a confirmed ALS diagnosis should be offered Rilutek.

Q. Is Rilutek available in India? Rilutek can be supplied to hospitals, neurology centres, and pharmacies across India through licensed pharmaceutical distributors. Contact A.K. Pharma — medicine distributor in Delhi — for availability and pricing.

Q. What is the price of Rilutek in India? Rilutek price in India varies by pack size. Contact A.K. Pharma at 011 4172 6999 or WhatsApp +91 9810034827 for current pricing and bulk supply rates.

Q. How should Rilutek be taken? Rilutek should be taken on an empty stomach — at least 1 hour before or 2 hours after meals. Food significantly reduces absorption. The standard dose is 50mg twice daily (100mg total daily dose).

Q. Does A.K. Pharma supply Rilutek in bulk? Yes. A.K. Pharma supplies Rilutek in bulk to hospitals, neurology centres, ALS clinics, and pharmacies across Delhi and India. Contact us for bulk pricing and availability.

Why Order Rilutek from A.K. Pharma?

• Licensed medicine distributor in Delhi with all required drug licenses
• 100% genuine Rilutek sourced from authorized Sanofi distributors
• Reliable supply to neurology centres, hospitals, and pharmacies across India
• Bulk supply available with competitive pricing
• Prompt response to all quote requests
• Serving neurologists and ALS specialists across Delhi NCR and India

Contact A.K. Pharma for Rilutek Supply 📍 E-2/257A, 2nd Floor, Shastri Nagar, New Delhi 110052 📞 011 4172 6999 📱 WhatsApp: +91 9810034827 🌐 akpharma.in